Many type II RAF inhibitors, including tovorafenib, potently inhibit wild-type and altered BRAF and CRAF but are ARAF sparing, which may explain the pattern of pERK modulation observed in the NF1-LOF tumor cell lines treated with these agents. The gene discussed is BRAF; the disease is neoplasm.